Dr Rapeport is the Managing Director and Founder of RespiVert. He is also a visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London. Dr Rapeport graduated in Medicine and underwent further training at the Universities of Glasgow and Oxford. He previously worked at Pfizer Central Research and at GlaxoWellcome (GW).

At the merger of GlaxoSmithkline, Dr Rapeport was appointed Head (SVP) of the CEDD for Respiratory and Inflammatory Diseases. In this role, Dr Rapeport developed significant expertise in the discovery and development of candidate molecules by the inhaled and intra-nasal routes of administration.